Angelini Pharma Buys US Catalyst for $4.1 Billion in State-Backed Deal
Angelini is set to buy US-based Catalyst for $31.50 per share in a state-backed deal, expanding into rare neurological diseases and entering the US market.
/ 352 items
#XY Event-Driven Stocks↓
Dystrophin Miss Sends Entrada Shares Tumbling Despite Functional Win
Entrada DMD drug was safe and helped movement a bit, but low muscle protein results disappointed investors, stock -60%.
enGene Stock Crashes After Bladder Cancer Drug Shows Solid Safety but Disappointing Durability
enGene bladder cancer drug shows good safety and early response, but weak long-term results; stock drops ~66% after update.
Avalo Therapeutics Reports Strong Phase 2 Results for Abdakibart in Hidradenitis Suppurativa – Ready to Advance to Phase 3
Avalo’s abdakibart showed strong results in reducing HS symptoms in a Phase 2 trial, with a favorable safety profile and better outcomes than placebo.
Cytokinetics’ Myqorzo Succeeds Where Camzyos Failed: Positive Phase 3 Results in Non-Obstructive HCM
Cytokinetics’ (aficamten) met both primary endpoints in the Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy (nHCM). Already approved for obstructive HCM, the drug could soon double its market.
Viridian’s Elegrobart Scores Big Win in Chronic Thyroid Eye Disease Phase 3 Trial – Shares Soar
Viridian's drug for thyroid eye disease showed strong Phase 3 results, improving eye symptoms with simple injections and possible home use.